propiomazine   Click here for help

GtoPdb Ligand ID: 7284

Synonyms: CB-1678 | Largon® | WY-1359
Approved drug
propiomazine is an approved drug (FDA (1960))
Compound class: Synthetic organic
Comment: Propiomazine is an antipsychotic drug.
Marketed formulations may contain propiomazine hydrochloride (PubChem CID 71802).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 48.85
Molecular weight 340.16
XLogP 4.53
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCC(=O)c1ccc2c(c1)N(CC(N(C)C)C)c1c(S2)cccc1
Isomeric SMILES CCC(=O)c1ccc2c(c1)N(CC(N(C)C)C)c1c(S2)cccc1
InChI InChI=1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
InChI Key UVOIBTBFPOZKGP-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Used to treat the symptoms of many psychotic conditions. See the DrugBank link for further details. There is no information regarding approval for clinical use of this drug on the US FDA or European Medicines Agency websites. Individual national approval agencies may have granted marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This drug’s molecular mechanism of action (MMOA) is complex, involving antagonism of receptors for several neurotransmitters. The drug's antipsychotic effect is most likely due to antagonism of dopamine and serotonin 5-HT2 receptors. Antagonism of the histamine H1 receptor likely underlies the drug's sedative action. See the DrugBank link for further details.